Entera Bio Ltd. (ENTX) is priced at $1.16 after the most recent trading session. At the very opening of the session, the stock price was $1.19 and reached a high price of $1.20, prior to closing the session it reached the value of $1.19. The stock touched a low price of $1.13.
Recently in News on December 10, 2020, Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis. EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Entera Bio Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.2500 on 01/04/21, with the lowest value was $1.0700 for the same time period, recorded on 01/04/21.
Entera Bio Ltd. (ENTX) full year performance was -48.53%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Entera Bio Ltd. shares are logging -65.88% during the 52-week period from high price, and 16.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.00 and $3.40.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 276752 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Entera Bio Ltd. (ENTX) recorded performance in the market was 7.41%, having the revenues showcasing 0.87% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 21.59M, as it employees total of 21 workers.
Market experts do have their say about Entera Bio Ltd. (ENTX)
During the last month, 0 analysts gave the Entera Bio Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1565, with a change in the price was noted -0.3900. In a similar fashion, Entera Bio Ltd. posted a movement of -25.16% for the period of last 100 days, recording 333,763 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ENTX is recording 0.04 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Entera Bio Ltd. (ENTX)
Raw Stochastic average of Entera Bio Ltd. in the period of last 50 days is set at 30.00%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 30.00%. In the last 20 days, the company’s Stochastic %K was 37.33% and its Stochastic %D was recorded 31.33%.
Bearing in mind the latest performance of Entera Bio Ltd., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 7.41%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -35.56%, alongside a downfall of -48.53% for the period of the last 12 months. The shares increased approximately by 8.41% in the 7-day charts and went up by 3.57% in the period of the last 30 days. Common stock shares were driven by 0.87% during last recorded quarter.